☆ 4.6 Article

Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial

JAMA CARDIOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Peripheral Vascular Disease

Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association

Niteesh K. Choudhry et al.

Summary: The widespread treatment of hypertension and improvements in blood pressure have led to a decline in heart disease and stroke, but there is still a gap between public health targets and actual blood pressure control rates. Medication nonadherence is a key factor contributing to this gap, and the scientific statement aims to summarize its impact and strategies for improving adherence.

HYPERTENSION (2022)

Add to Collection

Article Peripheral Vascular Disease

Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial

Kazuomi Kario et al.

Summary: This study found no significant difference in ambulatory blood pressure reductions between renal denervation and a sham procedure in treated patients with resistant hypertension. Although the blood pressure reduction after renal denervation was similar to other sham-controlled studies, the unexpected greater reduction in the sham control group in this study highlights design issues that will be addressed in a new trial.

HYPERTENSION RESEARCH (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium

David E. Kandzari et al.

Summary: The clinical implications of hypertension drive the development of device-based therapies. The HARC document integrates expert consensus and regulatory perspectives to address challenges and unmet needs in treating hypertension.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Paul A. Heidenreich et al.

Summary: The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure provides patient-centric recommendations for the prevention, diagnosis, and management of heart failure, based on contemporary evidence and updated recommendations.

CIRCULATION (2022)

Add to Collection

Article Medicine, General & Internal

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial

Felix Mahfoud et al.

Summary: In this study, the long-term safety and efficacy of renal denervation were evaluated. The results showed that renal denervation produced a clinically meaningful and lasting blood pressure reduction up to 36 months, independent of concomitant antihypertensive medications and without major safety events.

LANCET (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial

Florian Rader et al.

Summary: This study assessed the long-term durability of ultrasound RDN in lowering blood pressure. The results showed that over a period of 36 months, patients experienced reduced blood pressure and improved blood pressure control, without any new long-term safety concerns.

EUROINTERVENTION (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Rajiv Agarwal et al.

Summary: This review covers the development of mineralocorticoid receptor antagonists (MRAs) over the last 80 years, discussing the differences in mechanisms and effects between nonsteroidal and steroidal MRAs. Nonsteroidal MRAs demonstrate important distinctions in distribution, binding mode, and gene expression compared to steroidal MRAs.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Review Peripheral Vascular Disease

Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension A Systematic Review and Meta-Analysis

Gianfranco Parati et al.

Summary: Single-pill combination (SPC) therapy was found to lead to improved adherence and persistence compared to free-equivalent combination (FEC) therapy in patients with hypertension, resulting in better blood pressure control. Studies showed that patients receiving SPCs had significantly enhanced adherence and lower likelihood of discontinuation compared to those receiving FECs. Moreover, SPC therapy led to significant reductions in both systolic and diastolic blood pressure at week 12, highlighting its potential benefits for patients with hypertension.

HYPERTENSION (2021)

Add to Collection

Article Peripheral Vascular Disease

2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement

George S. Stergiou et al.

Summary: The collaborators come from different countries and regions, representing experts in the field of hypertension research, working together to make contributions.

JOURNAL OF HYPERTENSION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparison of Long-Term Outcomes for Responders Versus Non-Responders Following Renal Denervation in Resistant Hypertension

Karl Fengler et al.

Summary: Observational data indicates that blood pressure response to renal sympathetic denervation is associated with improved long-term clinical outcomes. The study found that patients who responded to the treatment had significantly fewer major adverse cardiovascular events during a median follow-up period of 48 months compared to non-responders.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

Michel Azizi et al.

Summary: Renal denervation through ultrasound treatment shows promising results in reducing blood pressure for patients with resistant hypertension, with greater effectiveness compared to a sham procedure within 2 months and similar safety outcomes. This may provide an alternative approach for patients with resistant hypertension to avoid adding more antihypertensive medications.

LANCET (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. An individual participant-level data meta-analysis

Denis Pouchain

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Bertram Pitt et al.

Summary: Finerenone therapy improved cardiovascular outcomes in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, compared to placebo. The risk of the primary outcome event was significantly lower in the finerenone group, primarily driven by a reduction in hospitalization for heart failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Rajiv Agarwal et al.

Summary: This review summarizes the development of mineralocorticoid receptor antagonists over the past 80 years, focusing on the mechanisms of action and advantages of nonsteroidal MRAs.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies

Felix Mahfoud et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

Michael Bohm et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Peripheral Vascular Disease

Confounding Factors in Renal Denervation Trials Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension

David E. Kandzari et al.

HYPERTENSION (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies

Felix Mahfoud et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial

Michel Azizi et al.

CIRCULATION (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry

Felix Mahfoud et al.

EUROPEAN HEART JOURNAL (2019)

Add to Collection

Article Medicine, General & Internal

Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial

David E. Kandzari et al.

LANCET (2018)

Add to Collection

Article Medicine, General & Internal

Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial

Michel Azizi et al.

LANCET (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

2018 ESC/ESH Guidelines for the management of arterial hypertension

Bryan Williams et al.

EUROPEAN HEART JOURNAL (2018)

Add to Collection

Article Peripheral Vascular Disease

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

Robert M. Carey et al.

HYPERTENSION (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial

Michel Azizi et al.

CIRCULATION (2016)

Add to Collection

Review Peripheral Vascular Disease

Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges

Alexandre Persu et al.

CURRENT HYPERTENSION REPORTS (2016)

Add to Collection

Article Medicine, General & Internal

Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial

Michel Azizi et al.

LANCET (2015)

Add to Collection

Article Medicine, General & Internal

A Controlled Trial of Renal Denervation for Resistant Hypertension

Deepak L. Bhatt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Peripheral Vascular Disease

Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network

Brent M. Egan et al.

HYPERTENSION (2013)

Add to Collection

Review Peripheral Vascular Disease

Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension

GianLuca Colussi et al.

JOURNAL OF HYPERTENSION (2013)

Add to Collection

Article Cardiac & Cardiovascular Systems

Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients

Stacie L. Daugherty et al.

CIRCULATION (2012)

Add to Collection

Article Health Care Sciences & Services

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers

Kevin E. Thorpe et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.